secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001213900-24-100231
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY
--------------------------------------------------------------------------------

- Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.
- Q3 income from operations $0.8M (vs $0.02M YoY); net income $1.8M ($0.03 EPS) vs $0.07M.
- Nine-month net loss $4.7M ($0.07 per share) vs $4.9M loss in prior year; revenue down 41% due to inventory shortages.
- Cash at Sept 30, 2024: $1.3M, down from $2.5M at Dec 31, 2023.
- CEO expects full-year results materially lower than 2023; generic competition may affect future Endari sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390024100231/0001213900-24-100231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390024100231/ea0221824-8k_emma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-100231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer